Conditional gene expression has greatly facilitated the examination of the functions of particular gene products. Using the Cre/lox P switching expression system, we plan to develop efficient conditional transgene activation of hepatitis C virus core protein (HCV-C) cDNA (nucleotide 342-914) in the transgenic mice to overcome "immune tolerance" formed during the embryonic period and "immune escape" against hepatitis virus antigen in our project. To use this system in vivo, the dormant transgenic construct, i.e., pApoE-SCS-EGFP-HCV-C, was generated using techniques of standard molecular biology. The liverspecific human apoE promoter was here used to target expression of genes of interest (EGFP and HCV-C) to murine liver. Prior to generating the transgenic mice, the availability of Cre/lox P system and construct functionality were successfully verified by a cell-free recombination system and via checking the expression of EGFP and HCV-C in the human hepatoma cells at the mRNA and protein levels. These results suggest that the Cre/lox P system could tightly control expression of EGFP and HCV-C in vitro, which laid a solid foundation to conditionally activate expression of target gene(s) in transgenic mice by Cre-mediated site-specific recombination.
Hepatitis C virus (HCV) is not infectious in vivo except for primates, so the proper HCV culture system and inbred animal model are difficult to set up, which has hampered detailed analysis on viral life cycle and pathogenesis of HCV infection [1, 2] . Hepatitis B virus (HBV) and HCV transgenic mouse models have been created by microinjecting the full or selected parts of the virus genome into the fertilized eggs of inbred immunodificient mice to provid new insights into the pathogenesis of hepatitis and hepatocellular carcinoma (HCC) [3] [4] [5] [6] . A disadvantage of the transgenic animals produced by the consistent gene expression system is that they aren't immunocompetent for the transgene products. Therefore, the immune system of newborn transgenic mice can't recognize the exotic identity of viral antigens. However, in human chronic hepatitis C, hepatocyte injury is not directly caused by HCV infection, but is a consequence of the destruction of infected hepatocytes by cytotoxic lymphocytes [7] . In these HCV transgenic mice, the antigen genes express normally, but little pathological changes are observed in the liver and the serum alanine aminotransferase levels keep unchanged, indirectly suggesting that the immune system plays a rather important role in hepatitis pathogensis [3] [4] [5] [6] .
Recently, a development in transgene technology is the control of tissue/organ-specific target gene expression at particular developmental stage, to mimic HBV or HCV infection in immunocompetent transgenic mice like that in human. Two systems successfully and frequently employed are tetracycline-inducible system (tet-off system or tet-on system) and Cre/lox P site-specific recombinase system [8] [9] [10] . The tetracycline-inducible expression system is not very tight in controlling [8, 9, 11 ]. Chisari's lab has produced transgenic mice expressing HBV envelope protein or HCV core protein (HCV-C) by using the tet-off system. The results showed that the transgene expression was undetectable in utero or early life, but the transgene mice were tolerant to HBV envelope protein or HCV-C immunization (Chisari, 2003, personal communication) , which might be caused by the leakiness. New variants of the tetracycline-based regulatory elements that can minimize or eliminate leaky transgene expression have been tested successfully in vitro, but approaches that can be used to eliminate basal transgene leak in vivo have not been well characterized yet [11] .
The Cre-mediated gene in vivo and in vitro conditional activation/inactivation have been widely employed in the different research fields [12, 13] and the general strategy is fully demonstrated in Fig. 1(B) . In conjunction with the inducible system controlling Cre expression [8] [9] [10] , the administration of the cell-permeable Cre protein [14] [15] [16] or Cre-expressing adenovirus vector [12] , the Cre/lox P switching expression system is a true "off/on" system. The "off/on" nature of this regulation will be very useful to express hepatitis viruse antigen genes in a temporally restricted fashion and precisely define the immunological reactions against antigens and pathogenesis of HCV infection. used the Cre/lox P system to efficiently conditionally express the core, E1 and E2 protein genes in transgenic mice, which provided useful animal models for investigating host immune response and pathogenesis of HCV infection.
Spatially and temporally expressing HCV-C gene in immunocompetent transgenic mice can be mediated by Cre/lox P system, so that the host immune response against HCV infection and pathogenesis of HCV infection can be fully and precisely elucidated.
In the present study, the dormant transgene vector was generated, followed by in vitro identifying Cre/lox P system for availability and construct for functionality.
Materials and Methods

Materials
Human hepatoma cell line BEL-7402 was from Cell Bank, Center of Experimental Animals, Sun Yat-sen University. Lipofectamine Cre, EGFP and HCV-C gene expression was prevented by STOP sequence flanked by lox P sites. Upon recognition of the lox P site, Cre deleted the SCS along with one lox P site and ligated the apoE promoter to EGFP and HCV-C gene sequence. L, lox P site; apoE pA, human apoE poly(A) signal. 
Plasmid construction
For liver-specific expression of target gene in vivo, the transgene construct [ Fig. 1(A) ] containing enhanced green fluorescent protein (EGFP) and HCV-C gene under the control of the liver-specific apoE promoter was constructed as described in Sambrook et al. [23] . pApoE-HCV-C HCV-C cDNA (position 342-914) was amplified from pMA-HCV with primer HCV-C-FP/HCV-C-RP, and inserted into the T-vector of pMD18-T (TaKaRa) to contruct pMD18-T-HCV-C. The PCR reaction was set up for 7 min at 94 °C, followed by 30 cycles of 45 s at 94 °C, 45 s at 58 °C, 1 min at 72 °C, and a final cycle of 7 min at 72 °C. Forward primer HCV-C-FP: 5'-CGGAACGCGTATGAGC-ACAAATCCTAAACCTC-3' (MluI site underlined) Reverse primer HCV-C-RP: 5'-ATGACTCGAGCTATGA-AGACACTGGCACTGTAAC-3' (XhoI site underlined, and stop codon double-underlined) HCV-C fragment (573 bp) was recovered from pMD18-T-HCV-C by digestion with MluI and XhoI, and directionally subcloned into the MluI and XhoI sites in the polylinker (5'-KpnI-MunI-HpaI-MluI-ClaI-XhoI-3') of pLiv.7 (9.3 kb) to create pApoE-HCV-C, as verified by restriction enzyme digestion. pApoE-EGFP-HCV-C To generate the plasmid containing EGFP reporter gene, 742 bp EGFP gene segment was excised from pBI-EGFP (Clontech) by digestion with EcoRV and SpeI, blunted at the SpeI site, and subsequently subcloned into pApoE-HCV-C at the dephosphorylated HpaI site, designated pApoE-EGFP-HCV-C. The orientation of EGFP fragment inserted in the frame was identified with EcoRI.
pApoE-SCS-EGFP-HCV-C For conditional expression
of HCV-C in vitro and in vivo mediated by the Cre/lox P system, an expression vector with SCS between the promoter and the target coding sequence was generated. SCS fragment (about 1.487 kb) was amplified by PCR with primer SCS-FP/SCS-RP using pBS302 as template, and cloned into pMD18-T to give pMD18-T-SCS. PCR reactions involved 30 cycles of denaturation for 45 s at 94 °C, annealing for 45 s at 62 °C, and extension for 2 min at 72 °C. Forward primer SCS-FP: 5'-GCACGAATTCTCAAGC-TTAGGATCCG-3' (EcoRI site underlined) Reverse primer SCS-RP: 5'-ATTAGGTACCAGTGAA-CCTCTTCGAGG-3' (KpnI site underlined)
The KpnI-EcoRI SCS fragment released from pMD18-T-SCS was orientatively subcloned into KpnI and MunI sites of pApoE-EGFP-HCV-C to prepare pApoE-SCS-EGFP-HCV-C. This complete sequence of the dormant transgene was further verified by sequencing.
Identification of lox P sites in the vector by Cremediated in vitro recombination
The pApoE-SCS-EGFP-HCV-C was digested with Cre protein (Novagen) in vitro, followed by plasmid DNA transformation, restriction enzyme digestion and PCR to confirm lox P site sequence. Cre digestion on pApoE-SCS-EGFP-HCV-C was carried out according to the manufacturer's instructions.
Intracellular confirmation for recombination system
Cell transfection BEL-7402 cells were transiently transfected with plasmids mentioned in Fig. 4 to further test the function of pApoE-SCS-EGFP-HCV-C at cell level. The cell culture and transient transfection were performed as previously reported [24] .
BEL-7402 cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS, 10 mM HEPES, 2 mM L-glutamine (Sigma), 100 U/ml penicillin (Sigma), and 100 mg/ml streptomycin (Sigma), refreshed 2-3 times per week and passed when being confluent. The cells were kept at 5% CO 2 in a humidified 37 °C incubator. The day before transfection, BEL-7402 cells were added into 6-well culture plate, and transiently transfected with the corresponding plasmid (Fig. 4) according to the liposome-mediated transfection method using Lipofectamine TM 2000 once cells reached 50%-80% confluency. 6-10 h after transfection, transfecting solution was replaced with the complete medium. In pApoE-SCS-EGFP-HCV-C+Cre transfecting group, the complete medium and 10 µM His 6 -NLS-Cre-MTS (recombinant cell-permeable Cre protein) [14] were together added into the corresponding well after discarding the transfecting solution. The transfection experiment was repeated three times with 1 µg, 5 µg and 10 µg of each corresponding plasmid being employed, respectively. In addition, all the plasmids used for transfection were purified using EndoFree plasmid maxi kit (Qiagen) and non-linearized. EGFP assay 48-96 h after transfection, cells were screened for the EGFP expression under fluorescence microscopy (excitation 450-490 nm). Analysis of RNA using RT-PCR After activation of target genes, the HCV-C RNA level in BEL-7402 cells was examined by RT-PCR. RNA was isolated using the RNeasy mini kit (Qiagen) following the manufacturer's recommendations. Isolated RNA was fully treated with amplification grade RNase free DNase (Promega) at 37 °C for 30 min to remove any contaminating DNA, and then heated at 72 °C for 30 min to inactivate the DNase. A specific system for the amplification of HCV-C mRNA used was One-step mRNA selective RT-PCR kit (Ver. 1.1, TaRaKa). RT-PCR was carried out as recommended by the manufacturer with primer pairs HCV-C-FP/RP (PCR product size: about 573 bp). RT-PCR amplification was carried out: 30 min at 50 °C for RT, denaturation for 5 min at 85 °C; then a succession of 35 cycles as follows, 1 min at 85 °C, 1 min at 58 °C, 60 s at 72 °C; a final extension at 72 °C for 10 min. Human β-actin gene was used as an internal standard with following primers (product size being 758 bp): Sense primer: 5'-GATATCGCTGCGCTGGTCGT-3' Antisense primer: 5'-CGGAACCGCTCGTTGCCAAT-3' For β-actin mRNA, one-step RT-PCR was carried out: 30 min at 50 °C for RT; and then a succession of 30 cycles as follows, 85 °C for 1 min, 62 °C for 1 min, and 72 °C for 1 min. All experiments were performed in triplicate. 
Western blot analysis of HCV-C expression After activation of target genes, HCV-C expression in BEL-
Results
Construction of pApoE-SCS-EGFP-HCV-C
pApoE-HCV-C HCV-C was amplified by PCR, and inserted into pMD18-T to prepare pMD18-T-HCV-C and comfirmed by sequencing. After that, the 573 bp HCV-C cDNA was excised, isolated, purified, and subsequently directionally subcloned into the MluI and XhoI sites of pLiv.7 (8.3 kb) linearized with MluI and XhoI to give pApoE-HCV-C (8.873 kb), as confirmed by enzyme digestion (Fig. 2) . pApoE-EGFP-HCV-C The 742 bp EGFP segment was excised from pBI-EGFP with EcoRV and SpeI and blunted at SpeI site, and cloned into the dephosphorylated HpaI site of pApoE-HCV-C to obtain pApoE-EGFP-HCV-C (9.613 kb), which was verified by enzyme digestion
Fig. 2 Enzyme digestion identification of the resulting plasmid pApoE-SCS-EGFP-HCV-C by analysis
M2, λ-HindIII digest marker (TaKaRa); M3, DL2000+DL15000 marker (TaKaRa); 1, purified vector DNA (pLiv.7) for ligation; 2, purified insert HCV-C for ligation; 3, pApoE-HCV-C cut by MluI and XhoI; 4, pApoE-HCV-C digested by HpaI or by XhoI (data not shown); 5, blunted and purified insert EGFP for ligation; 6, pApoE-EGFP-HCV-C cut by EcoRI; 7, pApoE-EGFP-HCV-C digested by KpnI and MunI or KpnI (data not shown); 8, pApoE-SCS-EGFP-HCV-C digested by KpnI; 9, pApoE-EGFP-HCV-C digested by HindIII; 10, pApoE-SCS-EGFP-HCV-C cut by KpnI and HindIII; 11, SCS PCR product (1.487 kb) amplificated from pApoE-SCS-EGFP-HCV-C with primers P1/P2 specific for SCS; 12, a 1.560 kb NotI-segment of SCS excised from pBS302. (Fig. 2) . The orientation of EGFP insert in the frame was identified by EcoRI digestion. The positive recombinant showed 8.742 kb and 0.826 kb bands (Fig. 2) , while the inverted recombinant generated two fragments of 8 kb and 1.568 kb after EcoRI digestion (data not shown). pApoE-SCS-EGFP-HCV-C The 1.487 kb SCS amplified by PCR was cloned into the pMD18-T to give pMD18-T-SCS, and confirmed by sequencing. SCS fragment with KpnI-EcoRI site, released from pMD18-T-SCS, was targetedly subcloned into the KpnI and MunI sites of pApoE-EGFP-HCV-C to produce the final desired plasmid pApoE-SCS-EGFP-HCV-C (11.1 kb). The desired resulting pApoE-SCS-EGFP-HCV-C digested by KpnI showed a 11.1 kb band, while cut by HindIII produced 1.56 kb and 9.48 kb bands (Fig. 2) . The 1.56 kb, 1.4 kb and 8 kb fragments were excised from the resultant pApoE-SCS-EGFP-HCV-C through double enzyme digestion of KpnI and HindIII (Fig. 2) . Consequently the genes of interest, such as SCS flanked by directly repeated lox P sequences, EGFP and HCV-C, were successively positioned downstream of apoE promoter/intron and upstream of the apoE polyadenylation sequences/liver element to prepare the desired construct pApoE-SCS-EGFP-HCV-C [ Fig. 1(A) ].
Confirmation of lox P site sequences in the vector
In pApoE-SCS-EGFP-HCV-C, SCS was flanked by two lox P sites (Fig. 1) . The recombination event in vitro mediated by Cre between two lox P sites will led to the excision of the lox P-flanked ("floxed") intervening DNA sequence to create the resulting plasmid pApoE-lox P-EGFP-HCV-C. Under conditions used in this study, 1.487 kb of the intervening sequence between lox P sites was amplified efficiently by PCR using pApoE-SCS-EGFP-HCV-C as template, whereas actually Cre mediated recombination theoretically allowed amplification of an 84 bp PCR product that could not observed on the electrophoresis map (Fig. 3) . That Cre could excise efficiently STOP cassette between two lox P sites from pApoE-SCS-EGFP-HCV-C was verified by enzyme digestion analysis (Fig. 3) . Cre-mediated in vitro recombination
Cell-permeable
After recombination, the resulting plasmid (RP) and pApoE-SCS-EGFP-HCV-C (control) were employed to be substrate for enzyme digestion and template for PCR. M3, DL2000+DL15000 marker (TaKaRa); M4, λ-EcoT14I digest marker (TaKaRa); 1, pApoE-SCS-EGFP-HCV-C digested by HindIII; 2, RP digested by HindIII; 3, pApoE-SCS-EGFP-HCV-C digested by KpnI and HindIII; 4, RP digested by KpnI and HindIII; 5, pApoE-SCS-EGFP-HCV-C used as PCR template; 6, RP used as PCR template. stop sequence. Moreover, HCV-C activation expression further confirmed the availability of Cre/lox P system and construct functionality [ Fig. 4(B,C) ]. Taken together, these data demonstrate the tight and conditional regulation of EGFP and HCV-C expression mediated by the Cre/lox P switching expression system in the cell.
Discussion
Since the harmful transgene product will behave as a self antigen inducing negative selection of reactive T cells in the thymus, immunologic response can only be studied through a system by which the transgene will be expressed in the transgenic animal only when being induced at desired time points [8] [9] [10] . The Cre-mediated conditional expression system developed recently can dissolve this problem [17] [18] [19] . The Cre/lox P conditional transgene activation system stringently controlling HCV-C transgene expression in vivo and in vitro was well elucidated in Fig. 1(B) . In this system, the lox P 2 STOP cassette must locate between the desired promoter and target gene/ reporter gene to give the dormant transgenic construct. Transgenic mice carrying the dormant transgene can mate Cre transgenic mice to generate bi-transgenic mice, in which Cre could be inducibly expressed to evict the STOP sequence to activate the dormant transgene. Transgenic mice carrying the dormant transgene can also be administered with cell-permeable Cre protein or Cre-expressing virus vectors by intravenous injection to induce Cremediated recombination.
A critical issue in using the lox P 2 STOP strategy is that after recombination the remaining lox P site must not interfere with expression of the target transgene [13] . Because lox P contains two ATG translational start codons in one orientation, but not in the other, as verfied by sequencing, it is important that the lox P 2 STOP cassette be properly oriented (Fig. 2) so that there remains no false ATG codon that could interfere with downstream transgene expression after recombination [13, 25] . Generally speaking, Cre-mediated activation system can tightly control the expression of dormant transgenes [12, 13] .
The tissue specific expression of the recombinationally activated dormant transgene is regulated by the promoter specificity of the target transgene and Cre transgene. In this study, Cre-mediated excision was realized by the intravenous injection of cell-permeable Cre protein or Cre-expressing virus vectors. The liver-specific apoE promoter system was employed to target the expression of the viral proteins to the physiologically relevant site of hepatocyte after activated. Actually, when the target gene (s) is/are placed downstream of the human apoE promoter, and upstream of the apoE polyadenylation sequence [ Fig. 1(A) ], the high expression of target gene can be ensured [20, [26] [27] [28] .
The non-invasive visualization is the key for GFP to being able to monitor physiological and biochemical processes in vitro, in vivo and in real time [29] . In this study, EGFP gene served as a reporter gene to conveniently monitor the in vitro function of Cre/lox P system and the apoE promoter.
In summary, we conclude that the Cre/lox P switching expression system is able to successfully and stringently control the expression of the dormant transgene EGFP and HCV-C in the cultured human hepatoma cells, which lays a solid foundation for efficient and conditional HCV-C gene activation in transgenic mice by Cre-mediated site-specific recombination.
